ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The first publication on the impact of the EMR, defined as 3-month BCR::ABL1 transcript < 10% after conversion to the IS, analyzed data from 282 patients newly diagnosed with CP–CML and treated with front-line imatinib.